These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29146692)

  • 1. Prediction of
    Ingrisch M; Schöppe F; Paprottka K; Fabritius M; Strobl FF; De Toni EN; Ilhan H; Todica A; Michl M; Paprottka PM
    J Nucl Med; 2018 May; 59(5):769-773. PubMed ID: 29146692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
    Paprottka KJ; Schoeppe F; Ingrisch M; Rübenthaler J; Sommer NN; De Toni E; Ilhan H; Zacherl M; Todica A; Paprottka PM
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1185-1193. PubMed ID: 28197686
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
    J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.
    Ulrich G; Dudeck O; Furth C; Ruf J; Grosser OS; Adolf D; Stiebler M; Ricke J; Amthauer H
    J Nucl Med; 2013 Apr; 54(4):516-22. PubMed ID: 23447653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors.
    Soydal C; Kucuk ON; Bilgic S; Ibis E
    Ann Nucl Med; 2016 Jan; 30(1):29-34. PubMed ID: 26370716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.
    Fendler WP; Lechner H; Todica A; Paprottka KJ; Paprottka PM; Jakobs TF; Michl M; Bartenstein P; Lehner S; Haug AR
    J Nucl Med; 2016 Apr; 57(4):517-23. PubMed ID: 26742710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
    Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
    Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bi-Centric Independent Validation of Outcome Prediction after Radioembolization of Primary and Secondary Liver Cancer.
    Fabritius MP; Seidensticker M; Rueckel J; Heinze C; Pech M; Paprottka KJ; Paprottka PM; Topalis J; Bender A; Ricke J; Mittermeier A; Ingrisch M
    J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
    Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
    Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.
    Michl M; Lehner S; Paprottka PM; Ilhan H; Bartenstein P; Heinemann V; Boeck S; Albert NL; Fendler WP
    J Nucl Med; 2016 Mar; 57(3):355-60. PubMed ID: 26609176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival.
    Dunfee BL; Riaz A; Lewandowski RJ; Ibrahim S; Mulcahy MF; Ryu RK; Atassi B; Sato KT; Newman S; Omary RA; Benson A; Salem R
    J Vasc Interv Radiol; 2010 Jan; 21(1):90-5. PubMed ID: 19939705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
    Maleux G; Deroose C; Laenen A; Verslype C; Heye S; Haustermans K; De Hertogh G; Sagaert X; Topal B; Aerts R; Prenen H; Vanbeckevoort D; Vandecaveye V; Van Cutsem E
    Acta Oncol; 2016; 55(4):486-95. PubMed ID: 26625262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
    Rühl R; Seidensticker M; Peters N; Mohnike K; Bornschein J; Schütte K; Amthauer H; Malfertheiner P; Pech M; Ricke J
    Dig Dis; 2009; 27(2):189-99. PubMed ID: 19546558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.